Previous reports have indicated that small tumor-derived EVs, containing galectin 9 (LGALS9), can impair DC antigen presentation via downregulating the expression of HLA-A, CD40, CD86 and Transporter Associated with Antigen Processing 1 (TAP1) proteins, contributing significantly to tumor progression and poor prognosis [96]. The gene discussed is CD86; the disease is neoplasm.